Skip to content
Neuronet
Neuronet - The support action for EU research on neurodegeneration
  • ABOUT
        • Objectives
        • Glossary
        • Work Packages
        • Partners
        • Executive Committee
        • Task Forces
        • Working Groups
        • Scientific Coordination Board
  • EVENTS
        • 2021: Virtual event
        • 2020: Virtual Event
        • 2019: The Hague
        • Event Calendar
  • NEWS
        • Latest news
        • Neuronet newsletters
        • Neuronet in the Media
  • PROJECTS
        • Ongoing Projects
        • Completed Projects
        • Project Overview
        • Project Timescales
  • RESOURCES
        • Asset Map
        • Project Tools
        • Regulatory & HTA Decision Tool
        • Neuronet Tools
        • Neuronet Deliverables
        • Neuronet Presentations
        • Publications
        • Useful resources for young researchers
  • KNOWLEDGE BASE

RADAR-AD

Describing the Alzheimer’s disease data landscape: AETIONOMY researchers publish an article in Alzheimer’s & Dementia – Translational Research and Clinical Interventions

22nd December 202016th December 2020
Evaluating the Alzheimer’s disease data landscape: issues with heterogeneity, bias and interoperability

Longitudinal cohort studies are of particular value for research on progressive, neurodegenerative diseases like Alzheimer’s

King’s College London is recruiting a Research Assistant for supporting the RADAR-AD study

10th January 20222nd November 2020
Job opportunity

The King’s College London’s Institute of Psychiatry, Psychology and Neuroscience, is recruiting a Reserch Assistant

Showcasing IMI projects: Neuronet at #30AEC

4th November 202027th October 2020

Neuronet has been designed to boost synergy and collaboration across the projects of the Innovative

First RADAR-AD participant completes 2 month participation in RADAR-AD study

12th November 20207th October 2020
First RADAR-AD participant completes 2 month participation in RADAR-AD study

The first participant enrolled in the main RADAR-AD study has completed the two-month assessment period

Development of dashboards to improve data quality and completeness for clinical teams’ use in RADAR-AD

1st April 202210th September 2020
RADAR-AD Remote assessment of disease and relapse – Alzheimer’s disease

The RADAR-AD technical and clinical teams have co-developed dashboards to support the work of clinicians

RADAR-AD clinical study officially starts

4th November 202024th August 2020
RADAR study starts

The first participant to take part in the RADAR-AD study was included on 10 July

RADAR-AD launches its bi-yearly newsletter

4th November 20203rd July 2020
RADAR-AD Remote assessment of disease and relapse – Alzheimer’s disease

The RADAR-AD project (Remote Assessment of Disease And Relapse – Alzheimer’s Disease), which aims to

RADAR-AD project publishes “Behind-the-scenes” interview series with its researchers

14th January 202225th May 2020
RADAR-AD Remote assessment of disease and relapse – Alzheimer’s disease

To show the variety of work going on “behind-the-scenes” in RADAR-AD, the project has published

Impact of the COVID-19 pandemic on RADAR-CNS and RADAR-AD projects

4th November 202021st April 2020
Impact of the COVID-19 pandemic on RADAR-CNS and RADAR-AD projects

The worldwide COVID-19 pandemic has inevitably impacted several EU projects. The RADAR-CNS and RADAR-AD projects

Development of the digital RADAR-BASE platform within the framework of RADAR-AD and RADAR-CNS

21st January 20227th April 2020
Development of the digital RADAR-BASE platform within the framework of RADAR-AD and RADAR-CNS 800x535

The IMI RADAR-AD project aims to develop a digital platform to remotely collect data from smartphone applications, wearable devices

Post navigation
Older posts
Newer posts
← Previous Page1 Page2 Page3 Page4 Next →

LATEST NEWS

  • Neuronet publishes Frontiers in Neurology article, analysing the structure, assets and collaborative networks in the IMI neurodegeneration portfolio

    9th November 2022
    The Innovative Medicines Initiative (IMI) was launched in 2008, with an initial budget of €8bn.Read More
  • Spotlight on Early-Career researchers a Neuronet interview with Ilja Saris

    5th September 2022
    In this Neuronet spotlight on early-career researcher interview, we speak with Ilja Saris who worksRead More
  • Spotlight on Communication experts: A Neuronet Blog with Cindy Birck

    29th August 2022
    Neuronet is a Coordination and Support Action for the Innovative Medicines Initiative’s research projects onRead More
  • Webinar series: Mobilise-D presents its four patient cohorts

    25th August 2022
    Mobilise-D starts the autumn webinar series presenting the needs, technologies, protocols and user perspectives forRead More
  • Spotlight on Communication experts: A Neuronet Blog with Yoanna de Geus

    23rd August 2022
    Neuronet is a Coordination and Support Action for the Innovative Medicines Initiative’s research projects onRead More

Neuronet

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

Any information on this website solely reflects the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

 

 

Innovative Medicines InitiativeEU Flag logoEuropean Federation of Pharmaceutical Industries and Associations logoParksinson's UK logo

Disclaimer
About IMI
Legal notice
Privacy policy

@ 2019 – IMI-NEURONET

© 2026 - IMI-NEURONET
We use cookies to offer you a better browsing experience and to analyze site traffic. Read about how we use cookies and how you can control them in our Cookie Policy. If you continue to use this site, you consent to our use of cookies. AcceptCookie policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT